MX2019013210A - Factores de crecimiento recombinantes modificados de fibroblastos y usos terapéuticos de los mismos. - Google Patents
Factores de crecimiento recombinantes modificados de fibroblastos y usos terapéuticos de los mismos.Info
- Publication number
- MX2019013210A MX2019013210A MX2019013210A MX2019013210A MX2019013210A MX 2019013210 A MX2019013210 A MX 2019013210A MX 2019013210 A MX2019013210 A MX 2019013210A MX 2019013210 A MX2019013210 A MX 2019013210A MX 2019013210 A MX2019013210 A MX 2019013210A
- Authority
- MX
- Mexico
- Prior art keywords
- growth factors
- fibroblast growth
- therapeutic uses
- recombinant modified
- modified fibroblast
- Prior art date
Links
- 102000018233 Fibroblast Growth Factor Human genes 0.000 title 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
- C07K14/501—Fibroblast growth factor [FGF] acidic FGF [aFGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
Abstract
Aquí se describen polipéptidos de factor de crecimiento modificados de fibroblastos (FGF), composiciones farmacéuticas y medicamentos que incluyen dichos polipéptidos de FGF modificados, y métodos para emplear dichos polipéptidos de FGF modificados para tratar o prevenir afecciones que se benefician de la administración de FGF.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762502529P | 2017-05-05 | 2017-05-05 | |
US201762502540P | 2017-05-05 | 2017-05-05 | |
US201762584624P | 2017-11-10 | 2017-11-10 | |
PCT/US2018/031189 WO2018204847A2 (en) | 2017-05-05 | 2018-05-04 | Recombinant modified fibroblast growth factors and therapeutic uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2019013210A true MX2019013210A (es) | 2020-07-20 |
Family
ID=64016756
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019013210A MX2019013210A (es) | 2017-05-05 | 2018-05-04 | Factores de crecimiento recombinantes modificados de fibroblastos y usos terapéuticos de los mismos. |
Country Status (10)
Country | Link |
---|---|
US (2) | US11479591B2 (es) |
EP (1) | EP3619324A4 (es) |
JP (1) | JP2020518287A (es) |
KR (1) | KR20200078425A (es) |
CN (1) | CN111148755A (es) |
AU (1) | AU2018261021A1 (es) |
BR (1) | BR112019023260A2 (es) |
CA (1) | CA3062473A1 (es) |
MX (1) | MX2019013210A (es) |
WO (1) | WO2018204847A2 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020518287A (ja) | 2017-05-05 | 2020-06-25 | トレフォイル セラピューティクス,インク. | 組み換え修飾された繊維芽細胞成長因子及びその治療用途 |
WO2021261946A1 (ko) | 2020-06-26 | 2021-12-30 | 엘티소재주식회사 | 헤테로고리 화합물 및 이를 이용한 유기 발광 소자 |
CN117677394A (zh) * | 2021-05-14 | 2024-03-08 | 克拉里斯生物医疗股份有限公司 | 用于治疗眼部疾病的生长因子的组合物 |
CN113289005B (zh) * | 2021-07-06 | 2022-05-31 | 温州医科大学 | rhFGF-21在制备治疗干眼症药物中的应用 |
WO2023019218A1 (en) * | 2021-08-12 | 2023-02-16 | Trefoil Therapeutics, Inc. | Modified fibroblast growth factors for treating fibrotic diseases |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5552528A (en) * | 1986-03-03 | 1996-09-03 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bovine b-endothelial cell growth factor |
US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
GB2223496B (en) * | 1988-08-08 | 1992-05-27 | British Bio Technology | Synthetic gene encoding mature human acid fibroblast growth factor |
US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
GB9523946D0 (en) | 1995-11-23 | 1996-01-24 | Bayer Ag | Leukotriene antagonistic benzoic acid derivatives |
US20010006939A1 (en) * | 1997-10-03 | 2001-07-05 | Ralph W. Niven | Secretory leukocyte protease inhibitor dry powder pharmaceutical compositions |
AU1628101A (en) * | 1999-11-22 | 2001-06-04 | Millennium Pharmaceuticals, Inc. | Jaffa, a novel fibroblast growth factor family member and uses therefor |
WO2002014471A2 (en) * | 2000-08-15 | 2002-02-21 | Phage Biotechnology Corporation | A method of producing biologically active human acidic fibroblast growth factor and its use in promoting angiogenesis |
US20050227929A1 (en) | 2003-11-13 | 2005-10-13 | Masferrer Jaime L | Combination therapy comprising a Cox-2 inhibitor and an antineoplastic agent |
US7790682B1 (en) | 2003-12-02 | 2010-09-07 | The Florida State University Research Foundation, Inc. | Engineered human acidic fibroblast growth factors and associated methods |
WO2005061712A1 (en) * | 2003-12-10 | 2005-07-07 | Eli Lilly And Company | Muteins of fibroblast growth factor 21 |
US7595296B1 (en) | 2006-11-09 | 2009-09-29 | Florida State University Research Foundation, Inc. | Mutant polypeptides of fibroblast growth factor 1 |
US7659379B1 (en) | 2007-05-24 | 2010-02-09 | Florida State University Research Foundation, Inc. | Mutants of human fibroblast growth factor having increased stability and/or mitogenic potency |
EP2933264A3 (en) * | 2008-01-22 | 2015-12-09 | Araim Pharmaceuticals, Inc. | Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage |
US8461111B2 (en) | 2009-05-20 | 2013-06-11 | Florida State University Research Foundation | Fibroblast growth factor mutants having improved functional half-life and methods of their use |
US20110224404A1 (en) | 2010-03-11 | 2011-09-15 | Florida State University Research Foundation | Method for development of a peptide building block useful for de novo protein design |
JO3476B1 (ar) * | 2011-09-26 | 2020-07-05 | Novartis Ag | بروتينات مندمجة لعلاج الاضطرابات الايضية |
US20150253308A1 (en) * | 2013-05-03 | 2015-09-10 | Orasis | Compositions and methods of treating glaucoma |
DK3049100T3 (da) * | 2013-09-25 | 2020-03-02 | Trefoil Therapeutics Llc | Modificerede fibroblastvækstfaktorer-1 til behandling af øjenlidelser |
WO2015061361A1 (en) | 2013-10-21 | 2015-04-30 | Salk Institute For Biological Studies | Mutated fibroblast growth factor (fgf) 1 and methods of use |
WO2015198175A1 (en) * | 2014-06-27 | 2015-12-30 | Florida State University Research Foundation, Inc. | Design of fgf-1 mutants to effectively eliminate reactive cysteine residues |
WO2016172153A2 (en) | 2015-04-20 | 2016-10-27 | Salk Institute For Biological Studies | Fibroblast growth factor (fgf) 1 with mutation in the heparin binding domain and methods of use to reduce blood glucose |
EP3285793A4 (en) * | 2015-04-20 | 2018-10-10 | Salk Institute for Biological Studies | Fibroblast growth factor (fgf) 1 mutants and methods of use to reduce blood glucose |
EP3336178B1 (en) * | 2015-08-13 | 2020-03-18 | Fujifilm Corporation | Method for culturing pluripotent stem cells, method for manufacturing culture vessel, culture vessel, and scaffold material for culturing cells |
JP2020518287A (ja) | 2017-05-05 | 2020-06-25 | トレフォイル セラピューティクス,インク. | 組み換え修飾された繊維芽細胞成長因子及びその治療用途 |
-
2018
- 2018-05-04 JP JP2020511867A patent/JP2020518287A/ja active Pending
- 2018-05-04 AU AU2018261021A patent/AU2018261021A1/en active Pending
- 2018-05-04 KR KR1020197035895A patent/KR20200078425A/ko not_active Application Discontinuation
- 2018-05-04 CN CN201880044863.5A patent/CN111148755A/zh active Pending
- 2018-05-04 EP EP18794391.5A patent/EP3619324A4/en active Pending
- 2018-05-04 MX MX2019013210A patent/MX2019013210A/es unknown
- 2018-05-04 BR BR112019023260-5A patent/BR112019023260A2/pt unknown
- 2018-05-04 CA CA3062473A patent/CA3062473A1/en active Pending
- 2018-05-04 US US16/611,182 patent/US11479591B2/en active Active
- 2018-05-04 WO PCT/US2018/031189 patent/WO2018204847A2/en active Application Filing
-
2022
- 2022-09-07 US US17/939,238 patent/US20230130851A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20200190158A1 (en) | 2020-06-18 |
EP3619324A2 (en) | 2020-03-11 |
CA3062473A1 (en) | 2018-11-08 |
BR112019023260A2 (pt) | 2022-02-22 |
CN111148755A (zh) | 2020-05-12 |
WO2018204847A2 (en) | 2018-11-08 |
JP2020518287A (ja) | 2020-06-25 |
EP3619324A4 (en) | 2020-12-30 |
US11479591B2 (en) | 2022-10-25 |
KR20200078425A (ko) | 2020-07-01 |
AU2018261021A1 (en) | 2019-12-12 |
RU2019139358A (ru) | 2021-06-07 |
US20230130851A1 (en) | 2023-04-27 |
RU2019139358A3 (es) | 2021-08-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2019013210A (es) | Factores de crecimiento recombinantes modificados de fibroblastos y usos terapéuticos de los mismos. | |
PH12019501575A1 (en) | ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFá1 INHIBITORS AND USE THEREOF | |
SG10201805246XA (en) | Approximated parameter adaptation | |
IL281192A (en) | Interleukin-2 polypeptide conjugates and uses thereof | |
MX2017004488A (es) | Composiciones farmaceuticas que comprenden variantes peptidicos y metodos para su uso. | |
MX2022007994A (es) | Derivados de arilciclohexilamina y su uso en el tratamiento de trastornos psiquiátricos. | |
MX2021013417A (es) | Polipeptidos de union a la proteina del miembro a de la familia 12 del dominio de lectina tipo c (clec12a) y sus usos. | |
MX2019013363A (es) | Microparticulas de liberacion extendida y suspensiones de las mismas para terapia medica. | |
SG11201912799SA (en) | Recombinant human-basic fibroblast growth factor (rh-bfgf) and pharmaceutical composition comprising rh-bfgf | |
PH12021550289A1 (en) | Ox40-binding polypeptides and uses thereof | |
AU201815816S (en) | Inhaler | |
MX2021012659A (es) | Composiciones de seda para el cuidado del cabello. | |
EP3909975A4 (en) | NEW POLYPEPTIDE AND ITS THERAPEUTIC APPLICATION | |
PL3618848T3 (pl) | Biologicznie aktywne kompleksy i ich zastosowania terapeutyczne | |
PH12021550122A1 (en) | Solubilized apyrases, methods and use | |
GB201819200D0 (en) | Polypeptide and uses thereof | |
IL287187A (en) | An artificially replaced chromosome and its use | |
MX2020005344A (es) | Compuestos de pirazolopiridinona. | |
MX2020005342A (es) | Compuestos de pirazolopiridinona. | |
MX2020004058A (es) | Inhibidores de d-aminoacido oxidasa y sus usos terapeuticos. | |
IL283452A (en) | Gene therapy based on fibroblast growth factor 21 (fgf21) | |
GB202201001D0 (en) | Polypeptide and use thereof | |
AU2020234373A1 (en) | Novel peptide and use thereof | |
SG11201909851SA (en) | Peptide for inducing regeneration of tissue, and use thereof | |
EP3436608A4 (en) | MODIFIED FIBROBLAST GROWTH FACTORS AND USES THEREOF |